Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
| Image |  |
|---|---|
| Description | scientific article published in July 2003 |
| Author/s | |
| Publication date | July 1, 2003 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |